pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,762 catalysts · 4,686 phase readout · 2,347 8k filing · 285 earnings · 201 pdufa · 172 phase 2 completion · 73 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 14 catalysts2026-07-23: 2 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 0 catalysts2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout4,686
  • 8k filing2,347
  • earnings285
  • pdufa201
  • phase 2 completion172
  • phase 1 completion73
  • phase 2 initiation62
  • phase 1 initiation40
  • phase 1 2 completion35
  • phase 0 trial completion23
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    50
    ›Apr 24, 2026phase 2 3 initiation90d agoCentral South University Xiangya Hospital 3 — HL-1186 (Phase II/III Trial Initiation)HL-1186

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →HL-1186 →source: globaldata
    ›Apr 24, 2026phase 2 3 initiation90d agoPostgraduate Institute of Medical Education and Research — acetaminophen (Phase II/III Trial Initiation)acetaminophen ER

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →acetaminophen ER →source: globaldata
    ›Apr 24, 2026phase 3 completion90d agoChong Kun Dang Pharmaceutical Corp. — CKD-398 (Phase III Trial Completion)CKD-398

    Therapy area: Metabolic Disorders. Indication: Type 2 Diabetes

    full page →CKD-398 →source: globaldata
    ›Apr 24, 2026phase 3 completion90d agoImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd — timdarpacept (Phase III Trial Completion)timdarpacept

    Therapy area: Oncology. Indication: Chronic Myelomonocytic Leukemia (CMML)

    full page →timdarpacept →source: globaldata
    ›Apr 24, 2026phase 3 completion90d agoBioClever 2005 SL — minoxidil (Phase III Trial Completion)minoxidil

    Therapy area: Dermatology. Indication: Androgenic Alopecia

    full page →minoxidil →source: globaldata
    ›Apr 24, 2026phase 3 completion90d agoShriners Hospitals for Children — bupivacaine ER (Phase III Trial Completion)bupivacaine

    Therapy area: Central Nervous System, Mouth and Dental Disorders. Indication: Post-Operative Pain, Unspecified Mouth and Dental Disorders

    full page →bupivacaine →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoPeople's College of Medical Sciences & Research Centre — formoterol (Phase IV Trial Initiation)formoterol

    Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

    full page →formoterol →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

    Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

    full page →melatonin →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoIxoreal Biomed Pvt Ltd — shatavari (Phase IV Trial Initiation)shatavari

    Therapy area: Hormonal Disorders, Women's Health. Indication: Menstrual Disorders, Unspecified Hormonal Disorders

    full page →shatavari →source: globaldata
    ›Apr 24, 2026phase iv trial initiation90d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →carboxymethylcellulose →source: globaldata
    ›Apr 24, 20268k filing90d agoHumacyte, Inc. (HUMA, HUMAW) — 8-K filingHumacyte, Inc.

    Items: 1.01, 7.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$ALT — Altimmune, Inc. (ALT) — 8-K filingAltimmune, Inc.

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d agoNEXGEL, INC. (NXGL, NXGLW) — 8-K filingNEXGEL, INC.

    Items: 3.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d agoNewAmsterdam Pharma Co N.V. (NAMS, NAMSW) — 8-K filingNewAmsterdam Pharma Co N.V.

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$PDSB — PDS Biotechnology Corp (PDSB) — 8-K filingPDS Biotechnology Corp

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$NVCR — NovoCure Ltd (NVCR) — 8-K filingNovoCure Ltd

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d agoProfusa, Inc. (PFSA, NVACW) — 8-K filingProfusa, Inc.

    Items: 1.01, 2.03, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$ONCO — Onconetix, Inc. (ONCO) — 8-K filingOnconetix, Inc.

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d agoMedicus Pharma Ltd. (MDCX, MDCXW) — 8-K filingMedicus Pharma Ltd.

    Items: 1.01, 3.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$QTTB — Q32 Bio Inc. (QTTB) — 8-K filingQ32 Bio Inc.

    Items: 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d agoScorpius Holdings, Inc. — 8-K filing

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$XBIO — Xenetic Biosciences, Inc. (XBIO) — 8-K filingXenetic Biosciences, Inc.

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$CTXR — Citius Pharmaceuticals, Inc. (CTXR) — 8-K filingCitius Pharmaceuticals, Inc.

    Items: 1.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$APGE — Apogee Therapeutics, Inc. (APGE) — 8-K filingApogee Therapeutics, Inc.

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$SANA — Sana Biotechnology, Inc. (SANA) — 8-K filingSana Biotechnology, Inc.

    Items: 5.02

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$TELO — Telomir Pharmaceuticals, Inc. (TELO) — 8-K filingTelomir Pharmaceuticals, Inc.

    Items: 1.01, 2.01, 3.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d agoANAPTYSBIO, INC (ANAB, ANABV) — 8-K filingANAPTYSBIO, INC

    Items: 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$CPIX — CUMBERLAND PHARMACEUTICALS INC (CPIX) — 8-K filingCUMBERLAND PHARMACEUTICALS INC

    Items: 5.07

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$ODYY — Odyssey Health, Inc. (ODYY) — 8-K filingOdyssey Health, Inc.

    Items: 1.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$NTHI — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) — 8-K filingNEONC TECHNOLOGIES HOLDINGS, INC.

    Items: 1.01, 3.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$BIOE — Bio Essence Corp (BIOE) — 8-K filingBio Essence Corp

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$HALO — HALOZYME THERAPEUTICS, INC. (HALO) — 8-K filingHALOZYME THERAPEUTICS, INC.

    Items: 5.03, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$MGTX — MeiraGTx Holdings plc (MGTX) — 8-K filingMeiraGTx Holdings plc

    Items: 1.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$INDP — Indaptus Therapeutics, Inc. (INDP) — 8-K filingIndaptus Therapeutics, Inc.

    Items: 5.02, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$IRD — Opus Genetics, Inc. (IRD) — 8-K filingOpus Genetics, Inc.

    Items: 2.03

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$LUCD — Lucid Diagnostics Inc. (LUCD) — 8-K filingLucid Diagnostics Inc.

    Items: 7.01, 8.01, 9.01

    full page →edgar 8k ↗
    ›Apr 24, 20268k filing90d ago$GRDX — GridAI Technologies Corp. (GRDX) — 8-K filingGridAI Technologies Corp.

    Items: 2.04

    full page →edgar 8k ↗
    ›Apr 25, 2026constraining patent expiry europe89d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Europe))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026patent expiry89d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026phase 0 trial completion89d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

    full page →EXG-202 →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

    Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

    full page →influenza (trivalent, split virion) vaccine →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoHenan Cancer Hospital — GH-2616 (Phase I Trial Completion)GH-2616

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer

    full page →GH-2616 →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

    Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

    full page →YTS-109 →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata
    ›Apr 25, 2026phase 1 completion89d agoAin Shams University — Ketalar (Phase I Trial Completion)Ketalar

    Therapy area: Central Nervous System. Indication: Post-Operative Pain

    full page →Ketalar →source: globaldata
    ›Apr 25, 2026phase 1 2 completion89d agoGeneral Hospital of the People's Liberation Army — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma, Splenic Marginal Zone B-Cell Lymphoma

    full page →cyclophosphamide →source: globaldata
    ›Apr 25, 2026phase 1 2 completion89d agoShanghai YaKe Biotechnology Co Ltd — CD7 CAR-T Cells (Phase I/II Trial Completion)CD7 CAR-T Cells

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

    full page →CD7 CAR-T Cells →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoAssiut University — dexamethasone (Phase II Trial Completion)dexamethasone

    Therapy area: Other Diseases. Indication: Other Disease

    full page →dexamethasone →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoTianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)Efudex

    Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)

    full page →Efudex →source: globaldata
    ›Apr 25, 2026phase 2 completion89d agoHai Phong Medical University — Biolizin (Phase II Trial Completion)Biolizin

    Therapy area: Central Nervous System. Indication: Appetite (Eating) Disorders

    full page →Biolizin →source: globaldata
    ← prev
    page 2 of 156
    next →
    $PFSA2.0000+2.56%
    $NXGLW0.03080.00%
    $NAMSW18.72-8.95%
    $PDSB0.7600+5.95%
    $ONCO0.8897-11.03%
    $QTTB15.41+2.46%
    $MDCX0.3877+9.52%
    $HUMAW0.00910.00%
    $ALT2.8200+0.36%
    $NVCR16.00+0.38%
    $CTXR0.5455+12.99%
    $APGE134.20+0.04%
    $SANA3.1600+0.64%
    $XBIO2.7000-3.91%
    $ANABV43.80+1.86%
    $TELO1.0800+17.49%
    $CPIX7.7000-1.91%
    $BIOE0.27000.00%
    $ODYY0.00600.00%
    $NTHI3.3700+3.06%
    $HALO78.60+1.96%
    $MGTX12.52+2.54%
    $INDP2.5200+2.44%
    $IRD3.0600+0.33%
    $GRDX3.5400+10.63%
    $LUCD0.9667-0.27%